Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 7/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.34 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586158 | 0.81 | IP6K1 (0.49) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586160 | 0.79 | IP6K1 (0.47) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586178 | 0.79 | IP6K1 (0.43) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586159 | 0.79 | IP6K1 (0.46) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586151 | 0.79 | IP6K1 (0.46) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586154 | 0.79 | IP6K1 (0.45) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586155 | 0.77 | IP6K1 (0.45) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL17586185 | 0.75 | IP6K1 (0.52) | IP6K1IP6K3IP6K2PARP1 | |
| SCHEMBL20457004 | 0.75 | PABPC1 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16132921 | 0.74 | SLC6A2 (0.34) | MTNR1AMTNR1BSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493426-B2 | Quinazolinone derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20160075666-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075666-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | FGFR1, FGFR3, FGFR2 | IP6K1 471/4885IP6K3 443/4885IP6K2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.